I
n the 30% of percutaneous coronary interventions (PCIs) being performed to treat symptoms of stable coronary artery disease (CAD), an ischemia-guided approach to revascularization is advocated over an anatomically guided approach.
Consequently, the appropriate use criteria for coronary revascularization emphasizes the presence of ischemic symptoms refractory to medical therapy and documentation of ischemia as justification of appropriate revascularization. To date, documentation of ischemia is largely performed by noninvasive imaging. However, noninvasive imaging has limited diagnostic accuracy due to its variable image quality, attenuation artifacts, and its inherent limitation in identifying relative, not absolute, myocardial flow.
This latter principle results in underestimation of the ischemic burden, particularly in patients with left main and multivessel CAD in whom the stakes are highest. It is not surprising, therefore, that although many interventional cardiologists value noninvasive imaging as a "gatekeeper" to the catheterization laboratory, they often witness its lack of accuracy in localizing vessel-or lesion-specific ischemia that is required for decision making regarding revascularization.
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